Akari Therapeutics Plc · NASDAQ:AKTX
Akari Therapeutics — Investor Presentation (June 2025)
19 slides from Akari Therapeutics's investor presentation, June 2025
Slide 1: Advancing Antibody Drug Conjugates With Novel Immuno-Oncology Payloads
June 2025 Advancing Antibody Drug Conjugates With Corporate Overview Novel Immuno-Oncology Payloads NASDAQ: AKTX akaritx.com
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation includes expressed or implied forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended (the Exchange Act), about the Akari Therapeutics, Plc
Slide 3: We Are Akari Therapeutics
WE ARE AKARI THERAPEUTICS Akari Therapeutics Is Focused on Innovating Antibody Drug Conjugates as Immuno-Oncology Therapies for Patients to Be Cancer Free 3
Slide 4: Senior Leadership Team With Deep Oncology/Biotech Experience
Senior Leadership Team With Deep Oncology/Biotech Experience Abizer Gaslightwala, Torsten Hombeck, PhD Satyajit Mitra, PhD Mark F. Kubik MS, MBA Chief Financial Officer Executive Director, Head of Business President, Head of Oncology Development – Oncology Chief Executive Officer Seasoned executive
Slide 5: Continued Momentum and Deal Flow in Early-Stage ADCs
Continued Momentum and Deal Flow in Early-Stage ADCs Licensee Licensor Phase Asset Target Date Deal Type Upfront Payment Total Deal Highlights $130M upfront + potential $70M in near-term milestones; Phase 2 2 ADCs CLDN18.2 5/2025 Licensing $130M $1.34B in development, regulatory and commercializatio
Slide 6: Why Akari
Why Akari Lead Payload: PH1 – spliceosome inhibitor Advancing Development of Inhibits RNA splicing needed to produce functional Antibody Drug Conjugates mRNAs before translation into proteins (ADCs) With Immuno- - Impact: Causes cell death and activates immune Oncology Payloads system in multiple wa
Slide 7: Why Akari Now: Strong Need For ADCs With New Payload Mechanisms
Why Akari Now: Strong Need For ADCs With New Payload Mechanisms Beyond Current ADC therapies In lung cancer, alternatives to ADCs with “Epitope Expression Persists in Circulating Tumor Cells as Breast Topo-1 Inhibitor payloads are needed Cancers Acquire Resistance to Antibody Drug Conjugates” For pa
Slide 8: Akari's ADC Molecules Are Designed Around Proprietary Novel Payload, PH1
Akari’s Antibody Drug Conjugate (ADC) Molecules Are Designed Around Our Proprietary Novel Payload, PH1 Highly Selective Cancer Cell Death Combined With Enhanced Immune System Engagement for Effective Tumor Eradication Payload Antibody Linker Novel PH1 Payload Induces Designed to Bind To a Specific C
Slide 9: Akari's Novel PH1 Payload Has Potential To Solve Significant Unmet Needs
Akari’s Novel PH1 Payload Has The Potential To Solve For These Significant Unmet Needs Within Oncology PH1 is an immuno-oncology payload that inhibits RNA splicing and induces cell death while activating the immune system Potential Advantages of ADCs With PH1 Payload Kills Cancer Cells While Synergy
Slide 10: PH1 Payload Is a Spliceosome Inhibitor
PH1 Payload Is a Spliceosome Inhibitor PH1 Binds Spliceosome Proteins SF3B1 and PH5 and Targets Normal Splicing of Pre-mRNA SSA DMSO PH1 0’ 30’ Various mRNA intermediates PH1 is a proprietary during the process of splicing Thailanstatin analog Lariat intermediate Thailanstatins, Free Lariat Spliceo
Slide 11: PH1's Mechanism of Action Generates Mis-Spliced Transcripts and Neoantigens
PH1’s Mechanism of Action Is Uniquely Selected for Generating Mis-Spliced Transcripts Leading to Immunogenic Neoantigens 9x Greater Than the Payload DM4 of Mirvetuximab Soravtansine Average (n=4 wells) expression of spliced RNA transcripts showing effect of DM4 (L, tubulin directed payload) and PH1
Slide 12: HER2 PH1 ADC Drives Significant Survival Benefit in Syngeneic Tumor Model
HER2 PH1 ADC Drives Significant Survival Benefit in Syngeneic HER2 Tumor Model Both As Single Agent and in I/O Combination Potent Activity of Her2-PH1 ADC As Single Agent PH1 Payload Induced Tumor-Specific and With Checkpoint Inhibitor Immune Memory Against Cancer Cells ADC Treatment and Survival Cu
Slide 13: Trop2 PH1 ADC Has Favorable Safety Profile in Non-Human Primate Study
Trop2 PH1 ADC Has Demonstrated Favorable Safety Profile in Non-Human Primate Study No toxicities such as interstitial lung disease, neutropenia, mucosal inflammation or neuropathies were observed Tolerated in NHP at doses well above Mitigatable side-effects that reset to efficacious dose baseline wi
Slide 14: Akari's Proprietary PH1 Payload Can Build An Entire ADC Pipeline
Akari’s Proprietary PH1 Payload Can Build An Entire ADC Pipeline Ability to Design Several Uniquely Targeted ADCs In Parallel Across Several Cancers Molecules Can Be Developed Internally Or Licensed To Partners For Immediate Value Application Targeting Antibody Proprietary Linkers Anti-Cancer Payloa
Slide 15: Akari Is Advancing PH1 Payload In Several ADC Programs
Akari Is Advancing PH1 Payload In Several ADC Programs PH1 payload being used to quickly build ADC pipeline against known and novel targets ADC Programs Indication Discovery Preclinical Clinical Highlights (All PH1 Payload based) Focus Areas: • Ready for GMP Manufacturing/ AKTX-101 Lung, Gastric GLP
Slide 16: Key Value Drivers - 2025
Key Value Drivers - 2025 H1 2025 H2 2025 Complete additional Presentation of key immuno-oncology preclinical studies for novel properties of PH1 payload at major PH1 payload validating scientific conference efficacy in prostate cancer cell lines Advance AKTX-102 proprietary antibody against novel ta
Slide 17: Legacy Non-Core Assets Beyond ADC Platform
Legacy Non-Core Assets Beyond ADC Platform Opportunity for Non-Dilutive Capital Through Ongoing Outlicensing Activities to Secure Development Partner for Inactive Programs Global Market Program Indication Discovery Preclinical Phase 1 Phase 2 Phase 3 Opportunity PAS-Nomacopan Long-Acting Complement
Slide 18: Why Now
Why Now Next-Generation Antibody Drug Conjugates Designed with Novel Immuno-Oncology Payload Innovative PH1 Payload Kills Targeted Cancer Cells and Activates Immune System To Kill Cancer Throughout Body AKTX-101 (TROP2 PH1 ADC) Ready For IND Enabling Studies With Partners AKTX-102 Combines PH1 Paylo
Slide 19: Thank You!
Thank You! Investor Relations Advancing Antibody Drug Conjugates With JTC Team aktx@jtcir.com Novel Immuno-Oncology Payloads (908) 824-0775
Akari Therapeutics — Investor Presentation (June 2025) on 6ix